US Edition
Tagrisso Gains Ground: AstraZeneca’s Strategic Edge in EGFR-Mutated Lung Cancer Battle
Summary by healtheconomics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Tagrisso Gains Ground: AstraZeneca’s Strategic Edge in EGFR-Mutated Lung Cancer Battle
AstraZeneca (AZ) is enhancing its strategic defense against Johnson & Johnson (J&J) in the competitive landscape of EGFR-mutated non-small cell lung cancer (NSCLC). AZ announced that its Tagrisso, when combined with chemotherapy, significantly extended patient survival compared to Tagrisso alone in first-line treatment of advanced EGFR-mutated NSCLC. This conclusion comes from the phase 3 Flaura2 trial, which revealed a 25% reduction in the risk…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium